Melanotan 2

Quick Facts

Introduction

Melanotan 2 (MT-2) is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous peptide that activates the melanocortin system. It is studied as a non-selective melanocortin-receptor agonist, meaning it engages several receptors of the melanocortin family rather than a single subtype. This broad activity is the reason MT-2 appears in research spanning pigmentation, appetite, and sexual behavior, and it shares its melanocortin origins with PT-141, a closely related compound.

The conceptual interest in MT-2 research is that the melanocortin system is a hub: the same family of receptors influences melanin production in the skin (via MC1R) and energy balance and sexual arousal in the brain (via MC4R). A single non-selective agonist therefore touches multiple pathways at once, which makes MT-2 a useful tool for probing melanocortin biology but also means its effects are inherently multi-system and difficult to isolate.

This profile covers what Melanotan 2 is, its cyclic alpha-MSH-derived structure, the melanocortin-receptor mechanisms it is studied for, and how it compares with related compounds such as PT-141 catalogued in the peptide database. Its multi-system activity is emphasized throughout as a key interpretive caveat.

What is Melanotan 2?

Melanotan 2 is a cyclic heptapeptide modeled on the active core of alpha-MSH. Native alpha-MSH is rapidly degraded and short-lived, so researchers designed MT-2 with two key changes: a cyclized backbone (a lactam bridge linking aspartate and lysine residues) that locks the active conformation, and substitutions including a D-phenylalanine that resist enzymatic breakdown. Together these make MT-2 far more stable and potent than the natural hormone.

Unlike its relative PT-141 (bremelanotide), which is a linear, ring-opened metabolite studied more narrowly for sexual-behavior endpoints, MT-2 retains the cyclic structure and a broader melanocortin-receptor profile. MT-2 is also distinct from Melanotan I (afamelanotide), a more MC1R-focused analogue. These distinctions matter because the receptor selectivity profile shapes which effects predominate in any given study.

Molecular and structural characteristics

Structurally, MT-2's defining feature is its cyclic constraint: a lactam bridge between an aspartate and a lysine side chain forms a ring that holds the peptide in the conformation that engages melanocortin receptors. The His-D-Phe-Arg-Trp core is the conserved 'message' sequence common to melanocortin agonists, with the D-amino-acid substitution conferring resistance to peptidases. Acetylation of the N-terminus and amidation of the C-terminus further stabilize the molecule.

Mechanism of action

Melanotan 2 acts as an agonist across the melanocortin-receptor family (MC1R through MC5R), all of which are G-protein-coupled receptors that raise intracellular cAMP when activated. Because MT-2 is non-selective, its overall effect is a composite of the actions of whichever receptors are engaged in a given tissue, which is the central feature researchers must account for when interpreting results.

At MC1R on melanocytes, agonism stimulates the cAMP-dependent pathway that up-regulates tyrosinase and drives melanin synthesis (melanogenesis) — specifically a shift toward darker eumelanin. This is the mechanism behind MT-2's most-studied pigmentation effect and is the reason it is catalogued under the tanning research category.

At MC4R in the central nervous system, agonism is associated with reduced food intake and with effects on sexual arousal and erectile function in preclinical models — the latter being the pathway that the linear analogue PT-141 was developed to exploit more selectively. MC3R and MC5R contributions are less well characterized but add to the multi-system nature of the compound.

• Non-selective agonism across melanocortin receptors MC1R–MC5R.
• MC1R activation associated with tyrosinase up-regulation and melanogenesis.
• MC4R activation linked to central appetite and sexual-behavior effects.
• Composite, multi-system activity due to lack of receptor selectivity.

Melanogenesis and pigmentation research

The pigmentation pathway is the most extensively studied aspect of MT-2. Through MC1R agonism, MT-2 is associated with increased melanin production by melanocytes in preclinical models, an effect that occurs largely independent of ultraviolet exposure — a contrast with normal sun-driven tanning, which requires UV-induced damage signaling. Researchers study this UV-sparing melanogenesis as a model for understanding melanocortin control of pigment.

The MC1R focus connects MT-2 conceptually to Melanotan I (afamelanotide), a more MC1R-selective analogue studied for a specific photoprotection indication. MT-2's broader receptor profile means pigmentation cannot be cleanly separated from its central effects, which is one reason researchers emphasize its non-selectivity when reporting pigmentation findings.

Central appetite and sexual-behavior research

Beyond pigmentation, MT-2 is studied for its central, MC4R-mediated effects. In preclinical models, melanocortin agonism is associated with reduced food intake, placing MT-2 within the broader research conversation about melanocortin control of energy balance. These appetite effects are distinct from the incretin pathway studied for compounds like semaglutide and arise from a different receptor system.

The other prominent central thread is sexual behavior. Observations that melanocortin agonism influenced arousal and erectile function in research models directly motivated the development of the linear analogue PT-141, which was refined to emphasize this pathway while reducing pigmentation activity. MT-2 thus sits upstream of PT-141 in the research lineage of melanocortin compounds.

Comparison: Melanotan 2 vs PT-141 vs Melanotan I

Melanotan 2 is most often compared with PT-141 (bremelanotide), its linear metabolite-derived relative, and with Melanotan I (afamelanotide), a more MC1R-selective analogue. All three are melanocortin compounds, but they differ in receptor selectivity and the effects they emphasize.

Researchers contrast Melanotan 2 with PT-141 to study how receptor selectivity shifts the balance between pigmentation and central effects. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

MT-2's cyclic, D-amino-acid-substituted structure gives it substantially greater metabolic stability and a longer duration of action than native alpha-MSH, whose half-life is only minutes. This enhanced stability is the entire design rationale: it converts a fleeting endogenous signal into a research-usable agonist. Reported half-life figures vary by model and are treated as approximate.

Because MT-2 is non-selective and reaches multiple tissues, its pharmacokinetics cannot be cleanly mapped to a single effect; the same circulating exposure simultaneously drives MC1R-mediated pigmentation and MC4R-mediated central actions. Researchers therefore interpret MT-2 exposure as a multi-system stimulus rather than a target-specific one.

Reconstitution and handling considerations

Melanotan 2 is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized Melanotan 2 is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled.

Research limitations

Melanotan 2 is a research compound whose non-selective melanocortin activity makes its effects inherently multi-system and difficult to isolate. Much of the available data come from preclinical models and limited research contexts, and reported effects on pigmentation cannot be separated from concurrent central effects. It is described here strictly for research reference.

• Non-selective receptor activity produces multi-system, hard-to-isolate effects.
• Much evidence comes from preclinical and limited research contexts.
• Reported effects are dose-, model-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996.Source
2. Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998.Source